Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
News|Articles|January 1, 2003
- Pharmaceutical Technology-01-01-2003
- Volume 27
- Issue 1
Analysis of the Indian Pharmaceutical Industry
Author(s)Hemant N. Joshi, PhD, MBA
India's pharmaceutical industry, which is one of the country's major economic sectors, is poised to make signficant gains on the global market.
Advertisement
Articles in this issue
over 23 years ago
Pharmaceutical Pricing and Innovation Key Issues for 2003over 23 years ago
Procedures: Improving Their Qualityover 23 years ago
Drug-Carrier Screening on a Chipover 23 years ago
Outsourcing Outlookover 23 years ago
Pack EXPO International 2002 Proves Worth the TripAdvertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Advertisement
Advertisement